Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Zelira Therapeutics (ZLDAF) Stock Price & Analysis

16 Followers

ZLDAF Stock Chart & Stats

$0.20$0.00(0.00%)
At close: 4:00 PM EST
$0$0.1$0.2Aug 10Aug 11Oct 26Oct 30
Day’s Range
$0.01 - $0.40
52-Week Range
$0.01 - $0.48
Previous Close
$0.20
Volume
N/A
Average Volume (3M)
57
Market Cap
$4.07M
Enterprise Value
$7.48M
Total Cash (Recent Filing)
$5,663
Total Debt (Recent Filing)
$2.14M
Price to Earnings (P/E)
―
Beta
-12.61
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Lean Cost Base (small Headcount)

A very small employee base implies a lean operating structure that can reduce fixed overhead and slow cash burn. Over 2-6 months this provides flexibility to allocate capital to priority projects or scale via outsourcing and partnerships rather than costly internal expansion.

Multi-channel Monetization Strategy

A dual pathway—consumer/product sales plus licensing and co-development—creates durable revenue optionality. Licensing can generate non-dilutive, recurring fees and milestone income, while commercialization upside remains if distribution partners scale sales, diversifying long-term cash sources.

Specialization In Cannabinoid Therapeutics & Consumer Health

A focused IP and product strategy in cannabinoid therapeutics and wellness (eg, sleep indications) aligns with structural industry interest in medical cannabis formulations. Specialized expertise and formulations are durable assets that can create niche competitive advantages if regulatory and commercial execution follow.

Bears Say

Severe Revenue Decline And Unprofitable Operations

An extreme revenue collapse and persistent negative margins indicate the core business is not currently monetizing at scale. Over the medium term this erodes operating leverage, undermines reinvestment capacity, and requires meaningful new revenue engines or partner deals to restore sustainable profitability.

Negative Shareholders' Equity / Balance-sheet Weakness

Negative equity signals deep capital shortfall and weak solvency. Structurally, this constrains access to traditional debt, raises refinancing and covenant risk, and increases likelihood of dilutive or costly capital raises—limiting strategic flexibility until the balance sheet is repaired.

Negative Operating And Free Cash Flows

Sustained negative operating and free cash flow means the business cannot self-fund R&D, regulatory work, or commercialization. Over a multi-month horizon this necessitates external financing, creating execution and timing risk for product launches, partnerships, and milestone realization.

Zelira Therapeutics News

ZLDAF FAQ

What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest stock price was $0.01 and its highest was $0.48 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is $4.07M.
When is Zelira Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zelira Therapeutics’s earnings last quarter?
Zelira Therapeutics released its earnings results on Aug 29, 2025. The company reported -$0.075 earnings per share for the quarter.
Is Zelira Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 13,147,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Zelira Therapeutics reported an EPS of -$0.075 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in ZLDAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology